FITLIFE BRANDS, INC. - Quarter Report: 2021 March (Form 10-Q)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
☒
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2021
|
☐
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES
EXCHANGE ACT
For the transition period from N/A to N/A
|
Commission File No. 000-52369
FITLIFE BRANDS, INC.
(Name of small business issuer as specified in its
charter)
Nevada
|
|
20-3464383
|
(State or other jurisdiction of incorporation)
|
|
(IRS Employer Identification No.)
|
5214 S.
136th Street, Omaha, NE 68137
(Address of principal executive offices)
(402) 991-5618
(Issuer’s telephone number)
(Former name, former address and former fiscal year, if changed
since last report)
Securities registered under Section 12(b) of the Exchange Act:
None
Securities
registered pursuant to Section 12(g) of the Exchange
Act:
Common Stock,
par value $0.01 per share
Indicate by check mark whether the Registrant
(1) has filed all reports required by Section 13 or 15(d)
of the Securities Exchange Act of 1934 during the preceding 12
months (or for such shorter period that the Registrant was required
to file such reports) and (2) has been subject to such filing
requirements for the past 90
days: Yes ☒ No ☐
Indicate by check mark whether the registrant has
submitted electronically every Interactive Data File required to be
submitted pursuant to Rule 405 of Regulation S-T (§232.405 of
this chapter) during the preceding 12 months (or for such shorter
period that the registrant was required to submit such files).
Yes ☒ No
☐
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated filer,
smaller reporting company or emerging growth company. See
definitions of “large accelerated filer,”
“accelerated filer,” “smaller reporting
company” and “emerging growth company” in Rule
12b-2 of the Exchange Act:
Large accelerated filer
|
☐
|
Accelerated filer
|
☐
|
Non–Accelerated filer
|
☒
|
Small reporting company
|
☒
|
|
|
Emerging growth company
|
☐
|
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended
transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the
Exchange Act. ☐
Indicate by check mark whether the registrant is a
shell company (as defined in Rule 12b–2 of the Exchange
Act). Yes ☐ No ☒
Indicate the number of shares outstanding of each of the
issuer’s classes of common stock, as of the latest
practicable date.
As of May 13, 2021, a total of 1,095,690
shares of the Registrant’s
Common Stock, par value $0.01 per share, were issued and
outstanding.
FITLIFE BRANDS, INC.
INDEX TO FORM 10-Q FILING
FOR THE QUARTER ENDED MARCH 31, 2021
TABLE OF CONTENTS
|
|
|
PAGE
|
|
1
|
||
|
|
|
|
|
1
|
||
|
|
|
|
|
|
1
|
|
|
|
2
|
|
|
|
3
|
|
|
|
4
|
|
|
|
5
|
|
|
|
|
|
|
14
|
||
|
|
|
|
|
20
|
||
|
|
|
|
|
21
|
||
|
|
|
|
|
22
|
||
|
|
|
|
|
22
|
||
|
|
|
|
|
22
|
||
|
|
|
|
|
22
|
||
|
|
|
|
|
22
|
||
|
|
|
|
|
22
|
||
|
|
|
|
|
22
|
Special Note Regarding Forward-Looking Statements
This Quarterly Report on Form 10-Q (“Quarterly
Report”), including “Management’s Discussion and
Analysis of Financial Condition and Results of Operations” in
Item 2 of Part I of this report, includes forward-looking
statements. These statements involve known and unknown risks,
uncertainties and other factors that may cause our actual results,
levels of activity, performance or achievements to be materially
different from any future results, levels of activity, performance,
or achievements expressed or implied by forward-looking
statements.
In some cases, you can identify forward-looking statements by
terminology such as “may”, “should”,
“expects”, “plans”,
“anticipates”, “believes”,
“estimates”, “predicts”,
“potential”, “proposed”,
“intended”, or “continue” or the negative
of these terms or other comparable terminology. You should read
statements that contain these words carefully, because they discuss
our expectations about our future operating results or our future
financial condition or state other “forward-looking”
information. There may be events in the future that we are not able
to accurately predict or control. Before you invest in our
securities, you should be aware that the occurrence of any of the
events described in this Quarterly Report could substantially harm
our business, results of operations and financial condition, and
that upon the occurrence of any of these events, the trading price
of our securities could decline and you could lose all or part of
your investment. Although we believe that the expectations
reflected in the forward-looking statements are reasonable, we
cannot guarantee future results, growth rates, levels of activity,
performance or achievements. We are under no duty to update any of
the forward-looking statements after the date of this Quarterly
Report to conform these statements to actual results.
PART I
FINANCIAL INFORMATION
Item 1. Financial Statements
FITLIFE BRANDS, INC.
ASSETS:
|
March 31,
|
December 31,
|
|
2021
|
2020
|
|
(Unaudited)
|
|
CURRENT
ASSETS
|
|
|
Cash
|
$6,625,000
|
$6,336,000
|
Accounts
receivable, net of allowance of doubtful accounts of $60,000 and
$51,000, respectively
|
2,372,000
|
2,044,000
|
Inventories,
net of allowance for obsolescence of $25,000 and $56,000,
respectively
|
4,738,000
|
3,401,000
|
Income
tax receivable
|
40,000
|
40,000
|
Prepaid
expenses and other current assets
|
22,000
|
52,000
|
Total
current assets
|
13,797,000
|
11,873,000
|
|
|
|
Property
and equipment, net
|
90,000
|
98,000
|
Right of
use asset, net of amortization of $285,000 and $272,000,
respectively
|
195,000
|
208,000
|
Goodwill
|
225,000
|
225,000
|
Deferred
tax asset
|
4,042,000
|
4,370,000
|
TOTAL
ASSETS
|
$18,349,000
|
$16,774,000
|
|
|
|
LIABILITIES
AND STOCKHOLDERS' EQUITY:
|
|
|
|
|
|
CURRENT
LIABILITIES:
|
|
|
Accounts
payable
|
$3,410,000
|
$3,246,000
|
Accrued
expense and other liabilities
|
590,000
|
498,000
|
Product
returns
|
304,000
|
335,000
|
Lease
liability - current portion
|
52,000
|
50,000
|
Total
current liabilities
|
4,356,000
|
4,129,000
|
|
|
|
Long-term
lease liability, net of current portion
|
144,000
|
158,000
|
PPP
loan
|
-
|
453,000
|
TOTAL
LIABILITIES
|
4,500,000
|
4,740,000
|
|
|
|
STOCKHOLDERS'
EQUITY:
|
|
|
Preferred
stock, $0.01 par value, 10,000,000 shares authorized, none
outstanding
|
|
|
as
of March 31, 2021 and December 31, 2020
|
|
|
Common
stock, $.01 par value, 15,000,000 shares authorized; 1,090,818 and
1,060,818
|
|
|
issued
and outstanding as of March 31, 2021 and December 31, 2020,
respectively
|
12,000
|
12,000
|
Treasury
stock, 210,631 and 210,631 shares, respectively
|
(1,790,000)
|
(1,790,000)
|
Additional
paid-in capital
|
32,335,000
|
32,204,000
|
Accumulated
deficit
|
(16,708,000)
|
(18,392,000)
|
TOTAL
STOCKHOLDERS' EQUITY
|
13,849,000
|
12,034,000
|
|
|
|
TOTAL
LIABILITIES AND STOCKHOLDERS' EQUITY
|
$18,349,000
|
$16,774,000
|
The
accompanying notes are an integral part of these condensed
consolidated financial statements
FITLIFE BRANDS, INC.
|
CONDENSED CONSOLIDATED STATEMENTS
OF OPERATIONS
|
FOR THE THREE MONTHS ENDED MARCH 31, 2021 AND 2020
(Unaudited)
|
|
Three months ended
|
|
|
March
31,
|
|
|
2021
|
2020
|
|
|
|
|
|
|
Revenue
|
$6,158,000
|
$6,151,000
|
Cost
of goods sold
|
3,081,000
|
3,414,000
|
Gross
profit
|
3,077,000
|
2,737,000
|
|
|
|
OPERATING
EXPENSES:
|
|
|
General
and administrative
|
857,000
|
733,000
|
Selling
and marketing
|
669,000
|
671,000
|
Depreciation
and amortization
|
8,000
|
12,000
|
Total
operating expenses
|
1,534,000
|
1,416,000
|
OPERATING
INCOME
|
1,543,000
|
1,321,000
|
|
|
|
OTHER
EXPENSES (INCOME)
|
|
|
Interest
expense (income)
|
(6,000)
|
4,000
|
Gain
on settlement
|
-
|
(70,000)
|
Gain
on debt forgiveness
|
(453,000)
|
-
|
Total
other expenses (income)
|
(459,000)
|
(66,000)
|
|
|
|
PRE-TAX NET
INCOME
|
2,002,000
|
1,387,000
|
|
|
|
PROVISION
(BENEFIT) FOR INCOME TAXES
|
318,000
|
(41,000)
|
|
|
|
NET
INCOME
|
$1,684,000
|
$1,428,000
|
|
|
|
NET INCOME
PER SHARE
|
|
|
Basic
|
$1.56
|
$1.36
|
Diluted
|
$1.43
|
$1.27
|
Basic
weighted average common shares
|
1,076,651
|
1,051,752
|
Diluted
weighted average common shares
|
1,174,666
|
1,126,303
|
The
accompanying notes are an integral part of these condensed
consolidated financial statements.
FITLIFE BRANDS, INC.
|
CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS'
EQUITY
|
FOR THE THREE MONTHS ENDED MARCH 31, 2021 AND 2020
|
(Unaudited)
|
|
|
|
|
Additional
|
|
|
|
Common Stock
|
Treasury
|
Paid-in
|
Accumulated
|
|
|
|
Shares
|
Amount
|
Stock
|
Capital
|
Deficit
|
Total
|
|
|
|
|
|
|
|
THREE
MONTHS ENDED MARCH 31, 2021
|
|
|
|
|
|
|
|
|
|
|
|
|
|
DECEMBER
31, 2020
|
1,060,818
|
$12,000
|
$(1,790,000)
|
$32,204,000
|
$(18,392,000)
|
$12,034,000
|
|
|
|
|
|
|
|
Repurchase
of common stock
|
-
|
-
|
-
|
-
|
-
|
-
|
Exercise of
stock options
|
-
|
-
|
-
|
-
|
-
|
-
|
Stock-based
compensation
|
30,000
|
-
|
-
|
131,000
|
-
|
131,000
|
Net
income
|
-
|
-
|
-
|
-
|
1,684,000
|
1,684,000
|
|
|
|
|
|
|
|
MARCH 31,
2021
|
1,090,818
|
$12,000
|
$(1,790,000)
|
$32,335,000
|
$(16,708,000)
|
$13,849,000
|
|
|
|
|
|
|
|
THREE
MONTHS ENDED MARCH 31, 2020
|
|
|
|
|
|
|
|
|
|
|
|
|
|
DECEMBER
31, 2019
|
1,054,516
|
$12,000
|
$(1,619,000)
|
$32,055,000
|
$(27,106,000)
|
$3,342,000
|
|
|
|
|
|
|
|
Fair value
of common stock issued for services
|
417
|
-
|
-
|
16,000
|
-
|
16,000
|
Repurchase
of common stock
|
(11,900)
|
-
|
(171,000)
|
-
|
-
|
(171,000)
|
Exercise of
stock options
|
17,000
|
-
|
-
|
71,000
|
-
|
71,000
|
Stock-based
compensation
|
-
|
-
|
-
|
12,000
|
-
|
12,000
|
Net
income
|
-
|
-
|
-
|
-
|
1,428,000
|
1,428,000
|
|
|
|
|
|
|
|
MARCH 31,
2020
|
1,060,033
|
$12,000
|
$(1,790,000)
|
$32,154,000
|
$(25,678,000)
|
$4,698,000
|
The
accompanying notes are an integral part of these condensed
consolidated financial statements.
FITLIFE BRANDS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF
CASH FLOWS
FOR THE THREE MONTHS ENDED MARCH 31, 2021 AND
2020
(Unaudited)
|
Three months ended
March 31,
|
|
|
2021
|
2020
|
|
|
|
CASH FLOWS
FROM OPERATING ACTIVITIES:
|
|
|
Net
income
|
$1,684,000
|
$1,428,000
|
Adjustments
to reconcile net income to net cash used in operating
activities:
|
|
|
Depreciation and amortization
|
8,000
|
12,000
|
Right of use asset amortization
|
14,000
|
16,000
|
Allowance for doubtful accounts
|
9,000
|
6,000
|
Allowance for inventory obsolescence
|
(31,000)
|
-
|
Fair value of stock and options issued for services
|
131,000
|
28,000
|
Forgiveness of PPP loan
|
(453,000)
|
-
|
Changes
in operating assets and liabilities:
|
|
|
Accounts
receivable - trade
|
(337,000)
|
(2,332,000)
|
Inventories
|
(1,307,000)
|
(25,000)
|
Deferred
tax asset
|
328,000
|
-
|
Prepaid
expense
|
30,000
|
46,000
|
Accounts
payable
|
164,000
|
737,000
|
Lease liability
|
(12,000)
|
(14,000)
|
Accrued
interest
|
-
|
4,000
|
Accrued
liabilities and other liabilities
|
92,000
|
75,000
|
Product
returns
|
(31,000)
|
20,000
|
Net
cash provided by operating activities
|
289,000
|
1,000
|
|
|
|
CASH
FLOWS FROM INVESTING ACTIVITIES:
|
|
|
Net
cash provided by investing activities
|
-
|
-
|
|
|
|
CASH
FLOWS FROM FINANCING ACTIVITIES:
|
|
|
Proceeds
from exercise of stock options
|
-
|
71,000
|
Proceeds
from line of credit
|
-
|
2,500,000
|
Repurchases
of common stock
|
-
|
(171,000)
|
Net
cash provided by financing activities
|
-
|
2,400,000
|
|
|
|
CHANGE
IN CASH
|
289,000
|
2,401,000
|
CASH,
BEGINNING OF PERIOD
|
6,336,000
|
265,000
|
CASH,
END OF PERIOD
|
$6,625,000
|
$2,666,000
|
|
|
|
Supplemental disclosure operating activities
|
|
|
Cash paid
for interest
|
$-
|
$-
|
Cash paid
(refunded) for income taxes
|
$(10,000)
|
$-
|
The
accompanying notes are an integral part of these condensed
consolidated financial statements.
FITLIFE BRANDS, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
FOR THE THREE MONTHS ENDED MARCH 31, 2021 AND 2020
(Unaudited)
NOTE 1 - DESCRIPTION OF BUSINESS
Summary
FitLife Brands, Inc. (the
“Company”) is a national provider of innovative and
proprietary nutritional supplements for health-conscious consumers
marketed under the following brand names: (i) NDS Nutrition, PMD
Sports, SirenLabs, CoreActive, and Metis Nutrition (together,
“NDS
Products”); and (ii)
iSatori, BioGenetic Laboratories, and Energize (together, the
"iSatori Products"). The
Company distributes the NDS Products principally through franchised General Nutrition
Centers, Inc. (“GNC”) stores located both domestically and
internationally, and, with the launch of Metis Nutrition, through
corporate GNC stores in the United States. The iSatori
Products are sold through more than 17,000 retail locations, which
include specialty, mass, and online.
FitLife Brands is headquartered in Omaha,
Nebraska. For more information on the Company, please go to
www.fitlifebrands.com.
The Company’s Common Stock, par value $0.01 per share
(“Common
Stock”), trades under the
symbol “FTLF” on the OTCQX market.
Recent Developments
Nutrology Asset Purchase
Subsequent to
the end of the quarter, on April 7, 2021, the Company purchased
substantially all of the assets of Triple Impact Corporation, a New
Jersey corporation doing business as Nutrology, a nutritional
supplement company catering to consumers who prioritize all-natural
and plant-based nutritional supplements.
Tax Benefits Preservation Plan
On February 26, 2021, the board of directors (the
“Board”) of the Company declared a dividend
distribution of one right (a “Right”) for each outstanding share of Common
Stock to stockholders of record at the close of business on
February 26, 2021 (the “Record Date”). Each Right entitles its holder, under
the circumstances described below, to purchase from the Company one
one-thousandth of a share of Series B Junior Participating
Preferred Stock of the Company, par value $0.01 per share (the
“Series B
Preferred”), at an
exercise price of $100.00 per Right, subject to adjustment. The
description and terms of the Rights are set forth in the tax
benefits preservation plan (the “Tax Benefits Preservation
Plan”), dated as of
February 26, 2021, between the Company and Colonial Stock, as
rights agent (and any successor rights agent, the
“Rights
Agent”).
The Company
adopted the Tax Benefits Preservation Plan in order to protect
shareholder value against a possible limitation on the
Company’s ability to use its Net Operating Losses
(“NOLs”) and
certain other tax benefits to reduce potential future U.S. federal
income tax obligations. The NOLs are a valuable asset to the
Company, which may inure to the benefit of the Company and its
stockholders. However, if the Company experiences an
“ownership change,” as defined in Section 382 of the
Internal Revenue Code (“IRC”), its ability to fully
utilize the NOLs and certain other tax benefits will be
substantially limited and the timing of the usage of the NOLs and
such other benefits could be substantially delayed, which could
significantly impair the value of those assets. Generally, an
“ownership change” occurs if the percentage of the
Company’s stock owned by one or more of its
“five-percent shareholders” (as such term is defined in
Section 382 of the IRC) increases by more than 50 percentage points
over the lowest percentage of stock owned by such stockholder or
stockholders at any time over a three-year period. The Tax Benefits
Preservation Plan is intended to prevent against such an
“ownership change” by deterring any person or group
from acquiring beneficial ownership of 4.9% or more of the
Company’s securities.
Share
Repurchase Plan
On February 1,
2021, the Board approved an additional amendment to the previously
authorized share repurchase program
initially approved by the Board of Directors (the
"Board") on August 16, 2019, as amended on September 23,
2019 and November 6, 2019 (“Share Repurchase
Program”). Under
the terms of the amendment, the Company is authorized to repurchase
up to $5.0 million of the Company's Common Stock, warrants to
purchase shares of the Company's Common Stock ("Warrants"), and other securities issued
by the Company ("Securities") over the next 24 months at
a purchase price, in the case of Common Stock, equal to the fair
market value of the Company's Common Stock on the date of purchase,
and in the case of Warrants and Securities, at a purchase price
determined by management, with the exact date and amount of such
purchases to be determined by management.
During the
three months ended March 31, 2021, the Company did not repurchase
any Securities under the Share Repurchase Program
Trade date
|
Total number of shares purchased
|
Average price paid per share
|
Total number of shares purchased as part of publicly
announced programs
|
Dollar value of shares that may yet be purchased
|
|
|
|
|
|
January
2021
|
-
|
$-
|
-
|
$1,110,917
|
February
2021
|
-
|
$-
|
-
|
$3,610,917
|
March
2021
|
-
|
$-
|
-
|
$3,610,917
|
Subtotal
|
-
|
$-
|
-
|
|
COVID-19 Pandemic
The
COVID-19 pandemic has had an effect on the Company’s
employees, business and operations and those of its customers,
vendors and business partners. In this respect, the temporary or
permanent closure of some of our retail partners’ store
locations and the stay-at-home orders that occurred early in the
pandemic negatively affected our results from operations, although
much of the impact has been offset by an increase in revenue
attributable to online sales, and increased sales during the more
recent quarters. Our future financial position and operating
results could be materially and adversely affected in the event
that a resurgence of COVID-19 cases leads to new stay-at-home
orders and/or disruptions in both our supply chain and
manufacturing lead-times, which could lower demand for the
Company’s products and/or prevent the Company from producing
and delivering its products in a timely manner, although the extent
of these effects cannot be determined at this time. The Company
expects to continue to assess the evolving impact of the COVID-19
pandemic and intends to make adjustments to its business and
operations accordingly.
CARES Act
The Coronavirus Aid, Relief, and Economic Security
Act ("CARES
Act") was enacted on March 27,
2020 in the United States. On April 27, 2020, the Company received
proceeds from a loan in the amount of $449,700 from its lender, CIT
Bank, N.A. (the “PPP Lender”), pursuant to approval by the U.S. Small
Business Administration (the “SBA”) for the PPP Lender to fund the
Company’s request for a loan under the SBA’s Paycheck
Protection Program (“PPP Loan”) created as part of the CARES ACT
administered by the SBA (the “Loan
Agreement”). In
accordance with the requirements of the CARES Act, the Company used
the proceeds from the PPP Loan primarily for payroll costs, covered
rent payments, and covered utilities during the eight-week period
commencing on the date of loan approval. The PPP Loan was scheduled
to mature on April 27, 2022, had a 1.0% interest rate, and was
subject to the terms and conditions applicable to all loans made
pursuant to the Paycheck Protection Program as administered by the
SBA under the CARES Act. The Company was informed by the PPP Lender
and the SBA that the full balance of the PPP Loan, including
accrued interest, was forgiven on January 15,
2021.
The CARES Act
permits employers to defer payment of the employer portion of
payroll taxes owed on wages paid through December 31, 2020 for a
period of up to two years. Through December 31, 2020, the Company
deferred payment of $77,000, which amount has been expensed and is
included in accrued liabilities.
NOTE 2 - BASIS OF PRESENTATION
The accompanying interim condensed unaudited
consolidated financial statements have been prepared in accordance
with generally accepted accounting principles for interim financial
information and with the instructions to Form 10-Q and Article 8 of
Regulation S-X. Accordingly, they do not include all of the
information and footnotes required by generally accepted accounting
principles for complete financial statements. In our opinion, all
adjustments (consisting of normal recurring accruals) considered
necessary for a fair presentation are included. Operating results
for the nine-month period ended March 31, 2021 are not
necessarily indicative of the results that may be expected for the
year ending December 31, 2021. Although management of the Company
believes the disclosures presented herein are adequate and not
misleading, these interim consolidated financial statements should
be read in conjunction with the audited consolidated financial
statements and the footnotes thereto included in our Annual Report
on Form 10-K for the fiscal year ended December 31, 2020, as filed
with the Securities and Exchange Commission ("SEC") on March 26, 2021.
NOTE 3 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
The Company prepares its financial statements in
accordance with accounting principles generally accepted in the
United States (“GAAP”). Significant accounting policies are
as follows:
Principles of Consolidation
The
condensed consolidated financial statements include the accounts of
the Company and its wholly owned subsidiaries. Intercompany
accounts and transactions have been eliminated in the consolidated
condensed financial statements.
Use of Estimates
The
preparation of financial statements in conformity with GAAP
requires management to make estimates and assumptions that affect
(i) the reported amounts of assets and liabilities,
(ii) the disclosure of contingent assets and liabilities known
to exist as of the date the financial statements are published, and
(iii) the reported amount of net sales and expense recognized
during the periods presented. Adjustments made with respect to the
use of estimates often relate to improved information not
previously available. Uncertainties with respect to such estimates
and assumptions are inherent in the preparation of financial
statements; accordingly, actual results could differ from these
estimates.
These
estimates and assumptions also affect the reported amounts of
accounts receivable, inventories, goodwill, revenue, costs and
expense and valuations of long-term assets, realization of deferred
tax assets and fair value of equity instruments issued for services
during the reporting period. Management evaluates these
estimates and assumptions on a regular basis. Actual results
could differ from those estimates.
Basic and Diluted Income (loss) Per Share
Our computation
of earnings per share (“EPS”) includes basic and diluted
EPS. Basic EPS is measured as the income (loss) available to common
stockholders divided by the weighted average common shares
outstanding for the period. Diluted income (loss) per share
reflects the potential dilution, using the treasury stock method,
that could occur if securities or other contracts to issue Common
Stock were exercised or converted into Common Stock or resulted in
the issuance of Common Stock that then shared in the income (loss)
of the Company as if they had been converted at the beginning of
the periods presented, or issuance date, if later. In computing
diluted income (loss) per share, the treasury stock method assumes
that outstanding options and warrants are exercised and the
proceeds are used to purchase Common Stock at the average market
price during the period. Options and warrants may have a dilutive
effect under the treasury stock method only when the average market
price of the Common Stock during the period exceeds the exercise
price of the options and warrants. Potential common shares that
have an antidilutive effect (i.e., those that increase income per
share or decrease loss per share) are excluded from the calculation
of diluted EPS.
|
Three months ended
March 31,
|
|
|
2021
|
2020
|
|
(unaudited)
|
|
Net income
available to common shareholders
|
$1,684,000
|
$1,428,000
|
Weighted
average common shares - basic
|
1,076,651
|
1,051,752
|
Dilutive
effect of outstanding warrants and stock options
|
98,015
|
74,551
|
Weighted
average common shares - diluted
|
1,174,666
|
1,126,303
|
|
||
Net income
per common share:
|
|
|
Basic
|
$1.56
|
$1.36
|
Diluted
|
$1.43
|
$1.27
|
Lease
We lease
certain corporate office space and office equipment under lease
agreements with monthly payments over a period of 36 to 84
months. We determine if an arrangement is a lease at
inception. Lease assets are presented as operating lease
right-of-use assets and the related liabilities are presented as
lease liabilities in our consolidated balance sheets.
Prior to
January 1, 2019, the Company accounted for leases under ASC 840,
Accounting for
Leases. Effective January 1, 2019, the Company
adopted the guidance of ASC 842, Leases, which requires an entity to
recognize a right-of-use asset and a lease liability for virtually
all leases. The Company adopted ASC 842 using a modified
retrospective approach. As a result, the comparative financial
information has not been updated and the required disclosures prior
to the date of adoption have not been updated and continue to be
reported under the accounting standards in effect for those
periods. The adoption of ASC 842 on January 1, 2019 resulted in the
recognition of operating lease right-of-use assets and lease
liabilities for operating leases of $480,000 and $480,000,
respectively. There was no cumulative-effect adjustment to
accumulated deficit. See Note 7 for further information regarding
the adoption of ASC 842 on the Company’s condensed
consolidated financial statements.
Goodwill
In January
2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other
(Topic 350): Simplifying the Accounting for Goodwill Impairment.
ASU 2017-04 removes Step 2 of the goodwill impairment test, which
required a hypothetical purchase price allocation. A goodwill
impairment will now be the amount by which a reporting unit’s
carrying value exceeds its fair value, not to exceed the carrying
amount of goodwill. This update also eliminated the requirements
for any reporting unit with a zero or negative carrying amount to
perform a qualitative assessment and, if it fails that qualitative
test, to perform Step 2 of the goodwill impairment test. The
Company adopted ASU 2017-04 on January 1, 2020 and applied the
requirements prospectively.
While we
have concluded that a triggering event did not occur during the
quarter ended March 31, 2021, a worsening of the severity of the
COVID-19 pandemic could result in future goodwill impairment
charges. We will continue to monitor the effects of the
COVID-19 pandemic’s impact on our business, and review for
impairment indicators as necessary in the upcoming
months.
Customer Concentration
Net
sales to GNC during the three-month periods ended March 31, 2021
and 2020 were $4,075,000 and $4,697,000, respectively, representing
66% and 76% of total net revenue, respectively.
Gross accounts receivable attributable
to GNC as of March 31, 2021 and 2020 were $1,992,000 and
$4,186,000, respectively, representing 87% and 91% of the Company’s total
accounts receivable balance, respectively.
For
the three months ended March 31, 2021 and 2020, online sales
accounted for 26% and 14% of the Company’s net revenue,
respectively.
Revenue Recognition
The
Company’s revenue is comprised of sales of nutritional
supplements to consumers, primarily through GNC
stores.
The Company
accounts for revenues in accordance with Accounting Standards
Codification (“ASC”) 606, Revenue from Contracts with Customers.
The underlying principle of ASC 606 is to recognize revenue to
depict the transfer of goods or services to customers at the amount
expected to be collected. ASC 606 creates a five-step model that
requires entities to exercise judgment when considering the terms
of contract(s), which includes (1) identifying the contract(s) or
agreement(s) with a customer, (2) identifying our performance
obligations in the contract or agreement, (3) determining the
transaction price, (4) allocating the transaction price to the
separate performance obligations, and (5) recognizing revenue as
each performance obligation is satisfied. Under ASC 606, revenue is
recognized when performance obligations under the terms of a
contract are satisfied, which occurs for the Company upon shipment
or delivery of products or services to our customers based on
written sales terms, which is also when control is transferred.
Revenue is measured as the amount of consideration we expect to
receive in exchange for transferring the products or services to a
customer.
All products
sold by the Company are distinct individual products and consist of
nutritional supplements and related supplies. The products are
offered for sale solely as finished goods, and there are no
performance obligations required post-shipment for customers to
derive the expected value from them.
Control of
products we sell transfers to customers upon shipment from our
facilities, and the Company’s performance obligations are
satisfied at that time. Shipping and handling activities are
performed before the customer obtains control of the goods and
therefore represent a fulfillment activity rather than promised
goods to the customer. Payments for sales are generally made by
check, credit card, or wire transfer. Historically the Company has
not experienced any significant payment delays from
customers.
For
direct-to-consumer sales, the Company allows for returns within 30
days of purchase. Our wholesale customers, such as GNC, may return
purchased products to the Company under certain circumstances,
which include expired or soon-to-be-expired products located in GNC
corporate stores or at any of its distribution centers, and
products that are subject to a recall or that contain an ingredient
or ingredients that are subject to a recall by the U.S. Food and
Drug Administration.
A right of
return does not represent a separate performance obligation, but
because customers are allowed to return products, the consideration
to which the Company expects to be entitled is variable. Upon
evaluation of returns, the Company determined that less than 5% of
products are returned, and therefore believes it is probable that
such returns will not cause a significant reversal of revenue in
the future. We assess our contracts and the reasonableness of our
conclusions on a quarterly basis.
Income Taxes
During the
quarter ended March 31, 2021, the Company recorded a federal income
tax expense of $328,000 and a state income tax benefit of $10,000.
During the quarter ended March 31, 2020, the Company received a tax
refund of $41,000 relating to a portion of the Company’s
alternative minimum tax carryforward, which became refundable as a
result of the 2017 Tax Cuts and Jobs Act.
The Company
recorded a 100% valuation allowance against its net deferred tax
assets as of March 31, 2020. During the fourth quarter of fiscal
2020, the Company determined that it is more likely than not that
it will be able to utilize the majority of its net operating loss
carryforwards. The release of a substantial portion of the reserve
against the Company’s deferred tax assets resulted in an
income tax benefit of $4,370,000 for 2020, and a corresponding
increase in net income of the same amount.
As of March 31, 2021, the Company had federal net
operating loss (“NOL”) carryforwards available to offset future
taxable income of approximately $20.0 million, resulting in a
deferred tax asset of approximately $4.2 million. A valuation
allowance of $537,000 has been recorded to reflect the portion of
such deferred tax asset that is not expected to be realized under
IRS statutory limitations.
The Company
accounts for income taxes using the asset and liability method,
whereby deferred tax assets are recognized for deductible temporary
differences, and deferred tax liabilities are recognized for
taxable temporary differences. Temporary differences are the
differences between the reported amounts of assets and liabilities
and their tax bases. Deferred tax assets are reduced by a valuation
allowance when, in the opinion of management, it is more likely
than not that some portion or all of the deferred tax assets will
not be realized, or that future deductibility is
uncertain.
Recent Accounting Pronouncements
Recent
accounting pronouncements issued by the FASB, including its
Emerging Issues Task Force, the American Institute of Certified
Public Accountants, and the SEC are not believed by management to
have a material impact on the Company’s present or future
financial statements.
NOTE 4 – INVENTORIES
The
Company’s inventory is carried at the lower of cost or net
realizable value using the first-in, first-out (“FIFO”) method. The Company
evaluates the need to record adjustments for inventory on a regular
basis. Company policy is to evaluate all inventories including
components and finished goods for all of its product offerings
across all of the Company’s operating
subsidiaries.
Total allowance
for expiring, excess and slow-moving inventory items as of March
31, 2021 and December 31, 2020 amounted to $25,000 and $56,000,
respectively. The Company’s
inventories as of March 31, 2021 and December 31, 2020 were as
follows:
|
March
31,
|
|
|
2021
|
December
31,
|
|
(unaudited)
|
2020
|
Finished
goods
|
$4,148,000
|
$2,789,000
|
Components
|
615,000
|
668,000
|
Allowance
for obsolescence
|
(25,000)
|
(56,000)
|
Total
|
$4,738,000
|
$3,401,000
|
NOTE 5 - PROPERTY AND EQUIPMENT
The Company’s fixed assets as of March 31,
2021 and December 31, 2020 were as
follows:
|
March
31,
|
|
|
2021
|
December
31,
|
|
(unaudited)
|
2020
|
Equipment
|
$902,000
|
$902,000
|
Accumulated
depreciation
|
(812,000)
|
(804,000)
|
Total
|
$90,000
|
$98,000
|
Depreciation
expense for the three months ended March 31, 2021 and 2020 was
$8,000 and $12,000, respectively.
NOTE 6 – NOTES PAYABLE
Line of Credit – CIT Bank
On
September 24, 2019, the Company entered into a Revolving Line of
Credit Agreement (the “Line
of Credit Agreement”) with Mutual of Omaha Bank, (the
“Lender”), subsequently
acquired by CIT Bank N.A., providing the Company with a $2.5
million line of credit (the “Line of Credit”). The Line of
Credit allows the Company to request advances thereunder and to use
the proceeds of such advances for working capital purposes until
the Maturity Date, unless renewed at maturity upon approval by the
Company’s Board of Directors and the Lender. The Line of
Credit is secured by all assets of the Company.
Advances
drawn under the Line of Credit bear interest at an annual rate of
the one-month LIBOR rate plus 2.75%, and each advance will be
payable on the Maturity Date with the interest on outstanding
advances payable monthly. The Company may, at its option, prepay
any borrowings under the Line of Credit, in whole or in part at any
time prior to the Maturity Date, without premium or
penalty.
On March
20, 2020, the Lender advanced the Company $2.5 million under the
Line of Credit, which amount was repaid on April 29, 2020. The
advance was intended to provide the Company with additional
liquidity given the uncertainty regarding the timing of collection
of certain accounts receivable and in anticipation of an expected
negative impact on sales to GNC and our other wholesale customers
resulting from the COVID-19 outbreak.
On August 4,
2020, the Company and the Lender amended the Line of Credit
Agreement to extend the Maturity Date to September 23, 2021. The
amendment also added a LIBOR floor of 75 bps to the Line of Credit
Agreement. All other terms of the Line of Credit Agreement remain
unchanged.
Paycheck Protection Program Loan
On April
27, 2020, the Company received proceeds from a loan in the amount
of $449,700 from the PPP Lender, pursuant to approval by the SBA
for the PPP Lender to fund the Company’s request for the PPP
Loan created as part of the recently enacted CARES Act administered
by the SBA. In accordance with the requirements of the CARES Act,
the Company used the proceeds from the PPP Loan primarily for
payroll costs, covered rent payments, and covered utilities during
the eight-week period commencing on the date of loan approval. The
PPP Loan was scheduled to mature on April 27, 2022, had a 1.0%
interest rate, and was subject to the terms and conditions
applicable to all loans made pursuant to the Paycheck Protection
Program as administered by the SBA under the CARES Act. The Company
was informed by the PPP Lender and the SBA that the full balance of
the PPP Loan, including accrued interest, was forgiven on January
15, 2021.
NOTE 7 - RIGHT OF USE ASSETS AND LIABILITIES
In prior years, the Company entered into several
non-cancellable leases for its office facilities and equipment. The
lease agreements range from 36 months to 84 months, and require
monthly payments ranging between $200 and $7,000 through October
2024. On January 1, 2019, the Company adopted Topic 842,
Leases
which requires a lessee to record a
right-of-use asset and a corresponding lease liability at the
inception of the lease initially measured at the present value of
the lease payments. The Company classified the leases as operating
leases and determined that the fair value of the lease assets and
liability at the inception of the leases was $480,000 using a
discount rate of 9%.
During the
three months ended March 31, 2021, the Company made payments
resulting in a $12,000 reduction in the lease liability. As of
March 31, 2021, lease liability amounted to $196,000. Topic
842 requires recognition in the statement of operations of a single
lease cost, calculated so that the cost of the lease is allocated
over the lease term, generally on a straight-line basis. Rent
expense, including real estate taxes, for the three months ended
March 31, 2021 was $16,000. The right-of-use asset at March
31, 2021 was $195,000, net of amortization of
$285,000.
|
Three months
ended
|
Lease
Cost
|
March 31,
2021
|
Operating
lease cost (included in general and administrative in the Company's
unaudited and consolidated statement of operations)
|
$16,000
|
|
|
Other
information
|
|
Cash paid
for amounts included in the measurement of lease liabilities for
the third quarter of 2021
|
$0
|
Weighted
average remaining lease term - operating leases (in
years)
|
3.6
|
Average
discount rate - operating leases
|
9%
|
The
supplemental balance sheet information related to leases for the
period is as follows:
Operating
leases
|
At
March 31,
2021
|
Long-term
right-of-use assets
|
$195,000
|
Short-term
operating lease liabilities
|
$52,000
|
Long-term
operating lease liabilities
|
144,000
|
Total
operating lease liabilities
|
$196,000
|
Maturities
of the Company's lease liabilities are as follows (in
thousands):
Year
ending
|
Operating
leases
|
2021
(remaining 3 months)
|
$50,000
|
2022
|
67,000
|
2023
|
61,000
|
2024
|
51,000
|
Less:
Imputed interest/present value discount
|
(33,000)
|
Present
value of lease liabilities
|
$196,000
|
NOTE 8 - EQUITY
Common Stock
a.
|
Common Stock
Issued for Services
|
The Company
is authorized to issue 15.0 million shares of Common Stock of which
1,090,818 shares of Common Stock were issued and outstanding as of
March 31, 2021.
In July 2018,
in connection with the appointment of Mr. Dayton Judd as Chief
Executive Officer, the Company granted Mr. Judd an aggregate of
45,000 shares of restricted Common Stock, which include vesting
conditions subject to the achievement of certain market prices of
the Company’s Common Stock. Such shares are also subject to
forfeiture in the event Mr. Judd resigns from his position or is
terminated by the Company. As the vesting of the 45,000 shares of
restricted Common Stock is subject to certain market conditions,
pursuant to current accounting guidelines, the Company determined
the fair value to be $105,000, computed using Monte Carlo
simulations on a binomial model with the assistance of a valuation
specialist using a derived service period of nine years. During the
three months ended March 31, 2021, the Company recorded
compensation expense of $3,000 to amortize the fair value of these
shares of restricted Common Stock based upon the prorated derived
service period. As of March 31, 2021, there
was no unearned compensation to be amortized as a compensation cost
associated with the grant of these shares.
In February
2021, the Company granted Mr. Judd an aggregate of 40,000
restricted share units (“RSUs”). Each RSU converts into
one share of the Company’s Common Stock upon vesting. The
RSUs vest as follows: (1) 10,000 shares at such date that the
30-day volume-weighted average price of Common Stock meets or
exceeds $30, (ii) 10,000 shares at such date that the 30-day
volume-weighted average price of Common Stock meets or exceeds $36,
(iii) 10,000 shares at such date that the 30-day volume-weighted
average price of Common Stock meets or exceeds $42, and (iv) 10,000
shares at such date that the 30-day volume-weighted average price
of Common Stock meets or exceeds $48. The RSUs are subject to
forfeiture in the event Mr. Judd resigns from his position or is
terminated by the Company. As the vesting of the RSUs is subject to
certain market conditions, pursuant to current accounting
guidelines, the Company determined the fair value to be $666,000,
computed using Monte Carlo simulations on a binomial model with the
assistance of a valuation specialist. During the quarter ended
March 31, 2021, the Company expensed $64,000 as a compensation
cost. As of March 31, 2021, there was $602,000 of unamortized
compensation expense associated with the grant of the
RSUs.
b.
|
Share
Repurchase Program
|
On August 16, 2019, the Company's Board authorized
management to repurchase up to $500,000 of the Company's Common
Stock over the next 24 months, which Share Repurchase Program was
previously reported on the Company's Current Report on Form 8-K
filed August 20, 2019. On September 23, 2019, the Board approved an
amendment to the Company’s Share Repurchase Program to
increase the repurchase of up to $1,000,000 of the Company's Common
Stock, its Series A Preferred, and Warrants, over the next 24
months, at a purchase price, in the case of Common Stock, equal to
the fair market value of the Company's Common Stock on the date of
purchase, and in the case of Series A Preferred and Warrants, at a
purchase price determined by management, with the exact date and
amount of such purchases to be determined by management. On
November 6, 2019, the Company’s Board of Directors amended
the previously approved Share Repurchase Program to increase the
amount of authorized repurchases to $2.5 million, and on February
1, 2021, the Company’s Board of Directors amended previously
approved Share Repurchase Program to increase the amount of
authorized repurchases to purchase up to $5.0 million. All
other terms of the Share Repurchase Program remain
unchanged.
During the three-month period ended March 31,
2021, the Company repurchased no shares of Common
Stock. The Company is
accounting for repurchased shares as treasury
stock.
Options
Information regarding options outstanding as of
March 31, 2021 is as follows:
|
Number of
|
Weighted Average
Exercise
|
Weighted Average Remaining Life
|
|
Options
|
Price
|
(Years)
|
Outstanding,
December 31, 2019
|
149,285
|
$11.76
|
5.0
|
Issued
|
-
|
|
|
Exercised
|
(17,000)
|
4.20
|
|
Forfeited
|
(36,500)
|
19.46
|
|
Outstanding,
December 31, 2020
|
95,785
|
$10.17
|
5.8
|
Issued
|
32,000
|
20.13
|
|
Exercised
|
-
|
|
|
Forfeited
|
(3,000)
|
13.90
|
|
Outstanding,
March 31, 2021
|
124,785
|
$12.64
|
5.5
|
|
Outstanding
|
Exercisable
|
|||
|
|
|
|
|
|
Exercise Price Per
share
|
Total Number of Options
|
Weighted Average Remaining Life (Years)
|
Weighted Average Exercise Price
|
Number of Vested Options
|
Weighted Average Exercise Price
|
|
|
|
|
|
|
$2.80-23.00
|
119,210
|
5.7
|
$9.01
|
95,210
|
$6.20
|
$23.10-144.34
|
5,575
|
2.5
|
$90.20
|
5,575
|
$90.20
|
|
124,785
|
5.5
|
$12.64
|
100,785
|
$10.85
|
During the
three-month periods ended March 31, 2021 and 2020, the Company
recognized compensation expense of $68,000 and $12,000,
respectively, to account for the fair value of stock options that
vested during the period.
Total intrinsic
value of outstanding stock options as of March 31, 2021 amounted to
$2,800,000. As of March 31, 2021 there
is $119,000 of unamortized compensation
expense.
Warrants
Total outstanding
warrants to purchase shares of Company Common Stock as of March 31,
2021 and December 31, 2020 amounted to 35,870 shares. Total intrinsic
value as of March 31, 2021 amounted to
$1,001,000.
During the
period ended March 31, 2021, no warrants were granted and no
warrants expired unexercised.
Outstanding
|
Exercise
Price
|
Issuance
Date
|
Expiration
Date
|
Vesting
|
35,870
|
$4.60
|
11/13/18
|
11/13/23
|
Yes
|
NOTE 9 – COMMITMENTS AND
CONTINGENCIES
We are
currently not involved in any litigation that we believe could have
a material adverse effect on our financial condition or results of
operations. There is no action, suit, proceeding, inquiry or
investigation before or by any court, public board, government
agency, self-regulatory organization or body pending or, to the
knowledge of the executive officers of the Company or any of its
subsidiaries, threatened against or affecting the Company, our
Common Stock, any of our subsidiaries or of the Company’s or
our subsidiaries’ officers or directors in their capacities
as such, in which an adverse decision could have a material adverse
effect.
NOTE 10
– SUBSEQUENT
EVENTS
Nutrology Asset Purchase
Subsequent to
the end of the quarter, on April 7, 2021, the Company purchased
substantially all of the assets of Triple Impact Corporation, a New
Jersey corporation doing business as Nutrology, a nutritional
supplement company catering to consumers who prioritize all-natural
and plant-based nutritional supplements.
Repurchase of Company Securities
In April, 2021, the Company, pursuant to its Share
Repurchase Plan, repurchased approximately $443,000 of its
Securities, as follows: (i) 12,710 in-the-money options were
repurchased from Company employees for approximately $186,000; and
(ii) 9,023 shares of Common Stock were repurchased from a member of
the Company’s Board of Directors for approximately
$257,000.
ITEM
2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
AND RESULTS OF OPERATIONS
The following discussion and analysis of our financial condition
and results of operations should be read in conjunction with our
financial statements and the related notes appearing elsewhere in
this Quarterly Report on Form 10-Q (this "Quarterly Report"). This
discussion and analysis may contain forward-looking statements
based on assumptions about our future business.
Overview
FitLife Brands, Inc. (the
“Company”) is a national provider of innovative and
proprietary nutritional supplements for health-conscious consumers
marketed under the following brand names: (i) NDS Nutrition, PMD
Sports, SirenLabs, CoreActive, and Metis Nutrition (together,
“NDS
Products”); and
(ii) iSatori, BioGenetic
Laboratories, and Energize (together,
“iSatori
Products”). The Company
distributes the NDS Products principally through franchised General
Nutrition Centers, Inc. (“GNC”) stores located both domestically and
internationally, and, with the launch of Metis Nutrition, through
corporate GNC stores in the United States. The iSatori
Products are sold through more than 17,000 retail locations, which
include specialty, mass, and online.
FitLife Brands is headquartered in Omaha,
Nebraska. For more information on the Company, please go to
www.fitlifebrands.com.
The Company’s common Stock, par value $0.01 per share
(“Common
Stock”), trades under the
symbol “FTLF” on the OTCQX market.
Recent Developments
Nutrology Asset Purchase
Subsequent to
the end of the quarter, on April 7, 2021, the Company purchased
substantially all of the assets of Triple Impact Corporation, a New
Jersey corporation doing business as Nutrology, a nutritional
supplement company catering to consumers who prioritize all-natural
and plant-based nutritional supplements.
Tax Benefits Preservation Plan
On February 26, 2021, the board of directors (the
“Board”) of the Company declared a dividend
distribution of one right (a “Right”) for each outstanding share of Common
Stock to stockholders of record at the close of business on
February 26, 2021 (the “Record Date”). Each Right entitles its holder, under
the circumstances described below, to purchase from the Company one
one-thousandth of a share of Series B Junior Participating
Preferred Stock of the Company, par value $0.01 per share (the
“Series B
Preferred”), at an
exercise price of $100.00 per Right, subject to adjustment. The
description and terms of the Rights are set forth in the tax
benefits preservation plan (the “Tax Benefits Preservation
Plan”), dated as of
February 26, 2021, between the Company and Colonial Stock, as
rights agent (and any successor rights agent, the
“Rights
Agent”).
The Company
adopted the Tax Benefits Preservation Plan in order to protect
shareholder value against a possible limitation on the
Company’s ability to use its net operating losses
(“NOLs”) and
certain other tax benefits to reduce potential future U.S. federal
income tax obligations. The NOLs are a valuable asset to the
Company, which may inure to the benefit of the Company and its
stockholders. However, if the Company experiences an
“ownership change,” as defined in Section 382 of the
Internal Revenue Code (the “IRC”), its ability to fully
utilize the NOLs and certain other tax benefits will be
substantially limited and the timing of the usage of the NOLs and
such other benefits could be substantially delayed, which could
significantly impair the value of those assets. Generally, an
“ownership change” occurs if the percentage of the
Company’s stock owned by one or more of its
“five-percent shareholders” (as such term is defined in
Section 382 of the IRC) increases by more than 50 percentage points
over the lowest percentage of stock owned by such stockholder or
stockholders at any time over a three-year period. The Tax Benefits
Preservation Plan is intended to prevent against such an
“ownership change” by deterring any person or group
from acquiring beneficial ownership of 4.9% or more of the
Company’s securities.
Share Repurchase Plan
On August 16, 2019, the Company's Board
authorized management to repurchase up
to $500,000 of the Company's Common Stock over the next 24 months
(the "Share
Repurchase Program"), which
Share Repurchase Program was previously reported on the Company's
Current Report on Form 8-K filed August 20, 2019. On September 23,
2019, the Board approved an amendment to the Company’s Share
Repurchase Program to increase the repurchase of up to $1,000,000
of the Company's Common Stock, its Series A Convertible Preferred
Stock, par value $0.01 per share ("Series A
Preferred"), and warrants to
purchase shares of the Company's Common Stock ("Warrants"), over the next 24 months, at a purchase price,
in the case of Common Stock, equal to the fair market value of the
Company's Common Stock on the date of purchase, and in the case of
Series A Preferred and Warrants, at a purchase price determined by
management, with the exact date and amount of such purchases to be
determined by management. On November 6, 2019, the
Company’s Board of Directors amended the previously approved
Share Repurchase Program to increase the amount of authorized
repurchases to $2.5 million. On February 1, 2021, the Board
approved an additional amendment to the previously authorized Share
Repurchase Program. Under the terms of the amendment, the Company
is authorized to repurchase up to $5.0 million. All other terms of
the Share Repurchase Program remain unchanged.
The Company intends to conduct its Share
Repurchase Program in accordance with all applicable securities
laws and regulations, including Rule 10b-18 of the Securities
Exchange Act of 1934, as amended (the "Exchange
Act"). Repurchases may be made
at management's discretion from time to time in the open market or
through privately negotiated transactions. The Company may suspend
or discontinue the Share Repurchase Program at any time, and may
thereafter reinstitute purchases, all without prior
announcement.
During the
three months ended March 31, 2021, the Company repurchased no
shares of Common Stock.
|
Total number of shares purchased
|
Average
price paid per share
|
Total number of shares purchased as part of publicly announced
programs
|
Dollar value
of shares that may yet be purchased
|
January
2021
|
-
|
$-
|
-
|
$1,110,917
|
February
2021
|
-
|
$-
|
-
|
$3,610,917
|
March
2021
|
-
|
$-
|
-
|
$3,610,917
|
Subtotal
|
-
|
$-
|
-
|
|
COVID-19 Pandemic
The
COVID-19 pandemic has had an effect on the Company’s
employees, business and operations and those of its customers,
vendors and business partners. In this respect, the temporary or
permanent closure of some of our retail partners’ store
locations and the stay-at-home orders that occurred early in the
pandemic negatively affected our results from operations, although
much of the impact has been offset by an increase in revenue
attributable to online sales, and increased sales during the most
recent quarter. Our future financial position and operating results
could be materially and adversely affected in the event that a
resurgence of COVID-19 cases leads to new stay-at-home orders
and/or disruptions in both our supply chain and manufacturing
lead-times, which could lower demand for the Company’s
products and/or prevent the Company from producing and delivering
its products in a timely manner, although the extent of these
effects cannot be determined at this time. The Company expects to
continue to assess the evolving impact of the COVID-19 pandemic and
intends to make adjustments to its business and operations
accordingly.
CARES Act
The Coronavirus Aid, Relief, and Economic Security
Act ("CARES
Act") was enacted on March 27,
2020 in the United States. On April 27, 2020, the Company received
proceeds from a loan in the amount of $449,700 from its lender, CIT
Bank, N.A. (the “PPP Lender”), pursuant to approval by the U.S. Small
Business Administration (the “SBA”) for the PPP Lender to fund the
Company’s request for a loan under the SBA’s Paycheck
Protection Program (“PPP Loan”) created as part of the recently enacted
CARES Act administered by the SBA (the “Loan
Agreement”). In
accordance with the requirements of the CARES Act, the Company
intends to use the proceeds from the PPP Loan primarily for payroll
costs, covered rent payments, and covered utilities during the
eight-week period commencing on the date of loan approval. The PPP
Loan was scheduled to mature on April 27, 2022, has a 1.0% interest
rate, and is subject to the terms and conditions applicable to all
loans made pursuant to the Paycheck Protection Program as
administered by the SBA under the CARES Act. The Company was
informed by the PPP Lender and the SBA that the full amount of
principal and accrued interest of the PPP Loan was forgiven on
January 15, 2021.
The CARES Act
permits employers to defer payment of the employer portion of
payroll taxes owed on wages paid through December 31, 2020 for a
period of up to two years. Through December 31, 2020, the Company
deferred payment of $77,000, which amount has been expensed and is
included in accrued liabilities.
Results of Operations
Comparison of the three months ended March 31, 2021 to the three
months ended March 31, 2020
|
Three months ended
|
|
|
|
|
March 31, 2021
|
March 31, 2020
|
Change
|
%
|
|
(unaudited)
|
|
|
|
Revenue
|
$6,158,000
|
$6,151,000
|
$7,000
|
0%
|
Cost of goods
sold
|
(3,081,000)
|
(3,414,000)
|
333,000
|
-10%
|
Gross profit
|
3,077,000
|
2,737,000
|
340,000
|
12%
|
Operating
expenses
|
(1,534,000)
|
(1,416,000)
|
(118,000)
|
8%
|
Income from
operations
|
1,543,000
|
1,321,000
|
222,000
|
17%
|
Other income
(expense)
|
459,000
|
66,000
|
393,000
|
|
Provision for income
tax
|
(318,000)
|
41,000
|
(359,000)
|
|
Net
income
|
$1,684,000
|
$1,428,000
|
$256,000
|
18%
|
Net
Sales. Revenue for
the three months ended March 31, 2021 was approximately flat
at $6,158,000 as compared
to $6,151,000 for the
three months ended March 31, 2020. The Company believes that a
portion of the revenue that historically would have been received
during the first quarter shifted into the fourth quarter of
2020.
Online
revenue during the three months ended March 31, 2021 was
approximately 26% and 14% of total revenue,
respectively.
Cost of Goods
Sold. Cost of goods
sold for the three months ended March 31, 2021 decreased
to $3,081,000 as compared to
$3,414,000 for the three months ended March 31, 2020. The
decrease in cost of goods sold during the three-month period ended
March 31, 2021 is primarily attributable to a greater percentage of
the Company’s revenue coming from online sales.
Gross
Profit. Gross profit for
the three months ended March 31, 2021 increased to $3,077,000 as compared to $2,737,000 for the
three months ended March 31, 2020. The increase during the three-month period is
principally attributable to a greater mix of online
sales.
Gross margin for the three months ended March 31,
2021 increased to 50.0% compared to 44.5% during the same
period last year.
General and Administrative
Expense. General and
administrative expense for the three months ended March 31,
2021 increased to $857,000 as
compared to $733,000 for the
three months ended March 31, 2020. The increase in the three-month period ended March 31, 2021
primarily reflects compensation expense of $131,000 related to
options and RSUs issued during the quarter.
Selling and Marketing
Expense. Selling and
marketing expense for the three months ended March 31, 2021
was roughly flat at $669,000 as
compared to $671,000 for the three months ended March 31,
2020.
- 16 -
Depreciation and Amortization
Expense. Depreciation and amortization expense
for the three months ended March 31, 2021 decreased
to $8,000 as compared to
$12,000 for the three months ended
March 31, 2020. The decrease in
the three-month period was primarily attributable to a reduction in
depreciation expense due to certain assets becoming fully
depreciated.
Net
Income. We generated net income of $1,684,000 for
the three-month period ended March 31, 2021 as compared to net
income of $1,428,000 for the three months ended March 31, 2020. The
increase in net income for the three-month period ended March 31,
2021 is primarily due to higher gross margins driven by an increase
in online sales and the forgiveness of the Company’s PPP
loan, partially offset by an increased provision for income
tax.
Non-GAAP
Measures
The financial
presentation below contains certain financial measures defined as
“non-GAAP financial measures” by the SEC, including
non-GAAP EBITDA and adjusted non-GAAP EBITDA. These measures may be
different from non-GAAP financial measures used by other companies.
The presentation of this financial information, which is not
prepared under any comprehensive set of accounting rules or
principles, is not intended to be considered in isolation or as a
substitute for the financial information prepared and presented in
this Annual Report in accordance with GAAP.
As presented
below, non-GAAP EBITDA excludes interest, income taxes, and
depreciation and amortization. Adjusted non-GAAP
EBITDA excludes, in addition to interest, taxes, depreciation
and amortization, equity-based compensation and non-recurring gains
or losses. The Company believes the non-GAAP measures provide
useful information to both management and investors by excluding
certain expense and other items that may not be indicative of its
core operating results and business outlook. The Company believes
that the inclusion of non-GAAP measures in the financial
presentation below allows investors to compare the Company’s
financial results with the Company’s historical financial
results and is an important measure of the Company’s
comparative financial performance.
|
For the three months ended
March 31,
|
|
|
2021
|
2020
|
|
(Unaudited)
|
(Unaudited)
|
Net
income
|
$1,684,000
|
$1,428,000
|
Interest
expense (income)
|
(6,000)
|
4,000
|
Provision
for income taxes
|
318,000
|
(41,000)
|
Depreciation
and amortization
|
8,000
|
12,000
|
EBITDA
|
2,004,000
|
1,403,000
|
Non-cash
and non-recurring adjustments
|
|
|
Stock
compensation expense
|
131,000
|
28,000
|
Non-recurring
losses (gains)
|
(453,000)
|
(70,000)
|
Adjusted EBITDA
|
$1,682,000
|
$1,361,000
|
Liquidity and Capital
Resources
At March 31,
2021, we had positive working capital of approximately $9,441,000,
compared to $7,744,000 at December 31, 2020. Our principal sources
of liquidity at March 31, 2021 consisted of $6,625,000 of cash and
$2,372,000 of accounts receivable.
On
September 24, 2019, the Company entered into a Revolving Line of
Credit Agreement (the “Line
of Credit Agreement”) with Mutual of Omaha Bank (the
“Lender”),
subsequently acquired by CIT Bank N.A., providing the Company with
a $2.5 million revolving line of credit (the “Line of Credit”). The Line of
Credit allows the Company to request advances thereunder and to use
the proceeds of such advances for working capital purposes until
the Maturity Date, or unless renewed at maturity upon approval by
the Company’s Board and the Lender. The Line of Credit is
secured by all assets of the Company.
Advances
drawn under the Line of Credit bear interest at an annual rate of
the one-month LIBOR rate plus 2.75%, and each advance will be
payable on the Maturity Date with the interest on outstanding
advances payable monthly. The Company may, at its option, prepay
any borrowings under the Line of Credit, in whole or in part at any
time prior to the Maturity Date, without premium or
penalty.
On March
20, 2020, the Lender advanced the Company $2.5 million under the
Line of Credit, which amount was repaid on April 29, 2020. The
advance was intended to provide the Company with additional
liquidity given the uncertainty regarding the timing of collection
of certain accounts receivable and in anticipation of an expected
negative impact on sales to GNC and our other wholesale customers
resulting from the COVID-19 outbreak.
On August 4,
2020, the Company and the Lender amended the Line of Credit
Agreement to extend the Maturity Date to September 23, 2021. The
amendment also added a LIBOR floor of 75 bps to the Line of Credit
Agreement. All other terms of the Line of Credit Agreement remain
unchanged.
On April
27, 2020, the Company received proceeds from a loan in the amount
of $449,700 from the PPP Lender, pursuant to approval by the SBA
for the Lender to fund the Company’s request for the PPP Loan
created as part of the recently enacted CARES Act administered by
the SBA. In accordance with the requirements of the CARES Act, the
Company used the proceeds from the PPP Loan primarily for payroll
costs, covered rent payments, and covered utilities during the
eight-week period commencing on the date of loan approval. The PPP
Loan was scheduled to mature on April 27, 2022, had a 1.0% interest
rate, and was subject to the terms and conditions applicable to all
loans made pursuant to the Paycheck Protection Program as
administered by the SBA under the CARES Act. The Company did not
provide any collateral or guarantees for the PPP Loan, nor did the
Company pay any fees to obtain the PPP Loan. The Company was
informed by the PPP Lender and the SBA that the full amount balance
of the PPP Loan, including accrued interest, was forgiven on
January 15, 2021.
The Company has historically financed its
operations primarily through cash flow from operations and equity
and debt financings. The Company has also provided for its
cash needs by issuing Common Stock, options and warrants for
certain operating costs, including consulting and professional
fees. The Company currently anticipates that cash derived
from operations and existing cash resources, along with available
borrowings under the new Line of Credit, will be sufficient to
provide for the Company’s liquidity for the next twelve
months.
The Company
is dependent on cash flow from operations and amounts available
under the Line of Credit to satisfy its working capital
requirements. No assurances can be given that cash flow from
operations and/or the Line of Credit will be sufficient to provide
for the Company’s liquidity for the next twelve months.
Should the Company be unable to generate sufficient revenue in the
future to achieve positive cash flow from operations, and/or should
capital be unavailable under the terms of the Line of Credit,
additional working capital will be required. Management currently
has no intention to raise additional working capital through the
sale of equity or debt securities and believes that the cash flow
from operations and available borrowings under the Line of Credit
will provide sufficient capital necessary to operate the business
over the next twelve months. In the event the Company fails to
achieve positive cash flow from operations, additional capital is
unavailable under the terms of the Line of Credit, and management
is otherwise unable to secure additional working capital through
the issuance of equity or debt securities, the Company’s
business would be materially and adversely
harmed.
Cash Provided by
Operations. Our cash
provided by operating activities for the three months ended March
31, 2021 was $289,000, as compared to cash provided by operations
of $1,000 for the three months ended March 31,
2020.
Cash Provided by Investing
Activities. There was no cash provided by or used in
investing activities for the three-month periods ended March 31,
2021 and 2020.
Cash Provided by Financing
Activities. Cash provided by
financing activities for the three months ended March 31,
2021 was $0 as compared to cash provided by financing
activities of $2,400,000 during the three months ended March 31,
2020.
Critical Accounting Policies and Estimates
Our discussion
and analysis of financial condition and results of operations is
based upon our consolidated financial statements, which have been
prepared in accordance with accounting principles generally
accepted in the United States of America ("GAAP"). The preparation of these
consolidated financial statements and related disclosures requires
us to make estimates and judgments that affect the reported amounts
of assets, liabilities, expense, and related disclosure of
contingent assets and liabilities. We evaluate, on an on-going
basis, our estimates and judgments, including those related to the
useful life of the assets. We base our estimates on historical
experience and assumptions that we believe to be reasonable under
the circumstances, the results of which form the basis for making
judgments about the carrying values of assets and liabilities that
are not readily apparent from other sources. Actual results may
differ from these estimates.
The methods,
estimates and judgments we use in applying our most critical
accounting policies have a significant impact on the results that
we report in our consolidated financial statements. The Securities
and Exchange Commission (the "SEC") considers an entity’s most
critical accounting policies to be those policies that are both
most important to the portrayal of a company’s financial
condition and results of operations and those that require
management’s most difficult, subjective or complex judgments,
often as a result of the need to make estimates about matters that
are inherently uncertain at the time of estimation. For a more
detailed discussion of the accounting policies of the Company, see
Note 3 of the Notes to the Condensed Consolidated Financial
Statements included in this Quarterly Report, “Summary of Significant Accounting
Policies”.
We believe the
following critical accounting policies, among others, require
significant judgments and estimates used in the preparation of our
consolidated financial statements.
Use of Estimates
The
preparation of financial statements in conformity with GAAP
requires management to make estimates and assumptions that affect
(i) the reported amounts of assets and liabilities,
(ii) the disclosure of contingent assets and liabilities known
to exist as of the date the financial statements are published, and
(iii) the reported amount of net sales and expense recognized
during the periods presented. Adjustments made with respect to the
use of estimates often relate to improved information not
previously available. Uncertainties with respect to such estimates
and assumptions are inherent in the preparation of financial
statements; accordingly, actual results could differ from these
estimates.
These
estimates and assumptions also affect the reported amounts of
accounts receivable, inventories, goodwill, revenue, costs and
expense and valuations of long-term assets, allowance for deferred
tax assets and equity instruments issued for services during the
reporting period. Management evaluates these estimates and
assumptions on a regular basis. Actual results could
differ from those estimates.
Goodwill
In January
2017, the FASB issued ASU 2017-04, Intangibles - Goodwill and Other
(Topic 350): Simplifying the Accounting for Goodwill Impairment.
ASU 2017-04 removes Step 2 of the goodwill impairment test, which
required a hypothetical purchase price allocation. A goodwill
impairment will now be the amount by which a reporting unit’s
carrying value exceeds its fair value, not to exceed the carrying
amount of goodwill. This update also eliminated the requirements
for any reporting unit with a zero or negative carrying amount to
perform a qualitative assessment and, if it fails that qualitative
test, to perform Step 2 of the goodwill impairment test. The
Company adopted ASU 2017-04 on January 1, 2020 and applied the
requirements prospectively.
While we
have concluded that a triggering event did not occur during the
quarter ended March 31, 2021, a worsening of the severity of the
COVID-19 pandemic could result in future goodwill impairment
charges. We will continue to monitor the effects of the
COVID-19 pandemic’s impact on our business, and review for
impairment indicators as necessary in the upcoming
months.
Revenue Recognition
The
Company’s revenue is comprised of sales of nutritional
supplements to consumers, primarily through GNC
stores.
The Company
accounts for revenues in accordance with Accounting Standards
Codification (“ASC”) 606, Revenue from Contracts
with Customers. The underlying principle of ASC 606 is to recognize
revenue to depict the transfer of goods or services to customers at
the amount expected to be collected. ASC 606 creates a five-step
model that requires entities to exercise judgment when considering
the terms of contract(s), which includes (1) identifying the
contract(s) or agreement(s) with a customer, (2) identifying our
performance obligations in the contract or agreement, (3)
determining the transaction price, (4) allocating the transaction
price to the separate performance obligations, and (5) recognizing
revenue as each performance obligation is satisfied. Under ASC 606,
revenue is recognized when performance obligations under the terms
of a contract are satisfied, which occurs for the Company upon
shipment or delivery of products or services to our customers based
on written sales terms, which is also when control is transferred.
Revenue is measured as the amount of consideration we expect to
receive in exchange for transferring the products or services to a
customer.
All products
sold by the Company are distinct individual products and consist of
nutritional supplements and related supplies. The products are
offered for sale solely as finished goods, and there are no
performance obligations required post-shipment for customers to
derive the expected value from them.
Control of
products we sell transfers to customers upon shipment from our
facilities, and the Company’s performance obligations are
satisfied at that time. Shipping and handling activities are
performed before the customer obtains control of the goods and
therefore represent a fulfillment activity rather than promised
goods to the customer. Payments for sales are generally made by
check, credit card, or wire transfer. Historically the Company has
not experienced any significant payment delays from
customers.
For
direct-to-consumer sales, the Company allows for returns within 30
days of purchase. Our wholesale customers, such as GNC, may return
purchased products to the Company under certain circumstances,
which include expired or soon-to-be-expired products located in GNC
corporate stores or at any of its distribution centers, and
products that are subject to a recall or that contain an ingredient
or ingredients that are subject to a recall by the U.S. Food and
Drug Administration.
A right of
return does not represent a separate performance obligation, but
because customers are allowed to return products, the consideration
to which the Company expects to be entitled is variable. Upon
evaluation of returns, the Company determined that less than 5% of
products are returned, and therefore believes it is probable that
such returns will not cause a significant reversal of revenue in
the future. We assess our contracts and the reasonableness of our
conclusions on a quarterly basis.
Recent Accounting Pronouncements
See Note 3 of
the Condensed Consolidated Financial Statements included in this
Quarterly Report for a description of recent accounting
pronouncements believed by management to have a material impact on
our present or future financial statements.
ITEM 3. QUANTITATIVE
AND QUALITATIVE DISCLOSURES ABOUT MARKET
RISK
Our
business is currently conducted principally in the United States.
As a result, our financial results are not materially affected by
factors such as changes in foreign currency exchange rates or
economic conditions in foreign markets. We do not engage in hedging
transactions to reduce our exposure to changes in currency exchange
rates although, as the geographical scope of our business broadens,
we may do so in the future.
Our
exposure to risk for changes in interest rates relates primarily to
any borrowings under our existing Line of Credit, and our
investments in short-term financial instruments. As of March 31,
2021, the Company had a zero balance under its existing Line of
Credit.
Investments
of our existing cash balances in both fixed rate and floating rate
interest-earning instruments carry some interest rate risk. The
fair value of fixed rate securities may fall due to a rise in
interest rates, while floating rate securities may produce less
income than expected if interest rates fall. Partly as a result of
this, our future interest income will vary due to changes in
interest rates and we may suffer losses in principal if we are
forced to sell securities that have fallen in estimated fair value
due to changes in interest rates. However, as substantially all of
our cash equivalents consist of bank deposits and short-term money
market instruments, we do not expect any material change with
respect to our net income as a result of an interest rate
change.
We do not
hold any derivative instruments and do not engage in any hedging
activities.
ITEM
4. CONTROLS AND
PROCEDURES
(a)
Evaluation of
Disclosure Controls and Procedures
We maintain
disclosure controls and procedures that are designed to ensure that
information required to be disclosed in our Exchange Act reports is
recorded, processed, summarized and reported within the time
periods specified in the SEC’s rules and forms and that such
information is accumulated and communicated to our Chief Executive
Officer and Chief Financial Officer, as appropriate, to allow for
timely decisions regarding required disclosure. In designing and
evaluating the disclosure controls and procedures, management
recognizes that any controls and procedures, no matter how well
designed and operated, can provide only reasonable assurance of
achieving the desired control objectives, and management is
required to apply its judgment in evaluating the cost-benefit
relationship of possible controls and procedures. Our disclosure
controls and procedures were designed to provide reasonable
assurance that the controls and procedures would meet their
objectives. As required by SEC Rule 13a-15(b), our Chief Executive
Officer and Chief Financial Officer carried out an evaluation of
the effectiveness of the design and operation of our disclosure
controls and procedures as of the end of the period covered by this
report. Based on the foregoing, our Chief Executive Officer and
Chief Financial Officer concluded that our disclosure controls and
procedures were effective at the reasonable assurance
level.
Our Chief Executive Officer and Chief Financial
Officer are responsible for establishing and maintaining adequate
internal control over our financial reporting. In order to evaluate
the effectiveness of internal control over financial reporting, as
required by Section 404 of the Sarbanes-Oxley Act, management has
conducted an assessment, including testing, using the criteria in
Internal Control — Integrated Framework, issued by the
Committee of Sponsoring Organizations of the Treadway Commission
(“COSO”). Our system of internal control over
financial reporting is designed to provide reasonable assurance
regarding the reliability of financial reporting and the
preparation of financial statements for external purposes in
accordance with generally accepted accounting principles. Because
of its inherent limitations, internal control over financial
reporting may not prevent or detect misstatements. Management has
used the framework set forth in the report entitled Internal
Control-Integrated Framework published by the COSO to evaluate the
effectiveness of our internal control over financial reporting.
Based on this assessment, our Chief Executive Officer and Chief
Financial Officer have concluded that our internal control over
financial reporting was effective as of March 31, 2021. This
Quarterly Report does not include an attestation report of the
Company's independent registered public accounting firm regarding
internal control over financial reporting. Management's report was
not subject to attestation by the Company's independent registered
public accounting firm pursuant to rules of the SEC that permit the
Company to provide only management's report in this Quarterly
Report. There has been no change in our internal controls over
financial reporting during our most recent fiscal quarter that has
materially affected, or is reasonably likely to materially affect,
our internal controls over financial reporting.
(b)
Changes in
Internal Controls Over Financial Reporting
The
Company's Chief Executive Officer and Chief Financial Officer have
determined that there have been no changes in our internal controls
over financial reporting or in other factors that could materially
affect, or are reasonably likely to affect, our internal controls
over financial reporting during the quarter ended March 31, 2021.
There have not been any significant changes in the Company’s
critical accounting policies identified since the Company filed its
Annual Report on Form 10-K for the year ended December 31,
2020.
PART
II
OTHER INFORMATION
ITEM 1. LEGAL
PROCEEDINGS
We
are currently not involved in any litigation that we believe could
have a material adverse effect on our financial condition or
results of operations. There is no action, suit, proceeding,
inquiry or investigation before or by any court, public board,
government agency, self-regulatory organization or body pending or,
to the knowledge of the executive officers of the Company or any of
its subsidiaries, threatened against or affecting the Company, our
Common Stock, any of our subsidiaries or of the Company’s or
our subsidiaries’ directors or officers in their capacities
as such, in which an adverse decision could have a material adverse
effect.
ITEM 1A. RISK
FACTORS
Our results
of operations and financial condition are subject to numerous risks
and uncertainties described in our Annual Report on Form 10-K for
our fiscal year ended December 31, 2020, filed on March 26, 2021.
You should carefully consider these risk factors in conjunction
with the other information contained in this Quarterly Report.
Should any of these risks materialize, our business, financial
condition and future prospects could be negatively
impacted.
ITEM 2. UNREGISTERED SALES OF
EQUITY SECURITIES
None.
ITEM 3. DEFAULTS UPON SENIOR
SECURITIES
There were no
defaults upon senior securities during the three-month period ended
March 31, 2021.
ITEM 5. OTHER
INFORMATION
None.
ITEM
6. EXHIBITS
|
Certified
of Designation, Preferences and Rights of Series B Junior
Participating Preferred Stock of FitLife Brands, Inc. (incorporated
by reference to Exhibit 3.1 filed with the Current Report on Form
8-K on March 4, 2021).
|
|
|
Tax
Benefit
Preservation Plan, dated February 26, 2021, by and between FitLife
Brands, Inc. and Colonial Stock Transfer Company, Inc.
(incorporated by reference to Exhibit 4.1 filed with the Current
Report on Form 8-K on March 4, 2021).
|
|
|
Certification
of Chief Executive Officer Pursuant to Section 302 of the
Sarbanes-Oxley Act.
|
|
|
Certification
of Chief Financial Officer Pursuant to Section 302 of the
Sarbanes-Oxley Act.
|
|
|
Certification
of Chief Executive Officer Pursuant to Section 906 of the
Sarbanes-Oxley Act.
|
|
|
Certification
of Chief Financial Officer Pursuant to Section 906 of the
Sarbanes-Oxley Act.
|
|
101.INS
|
|
XBRL Instance
Document
|
101.SCH
|
|
XBRL Taxonomy
Extension Schema
|
101.CAL
|
|
XBRL Taxonomy
Extension Calculation Linkbase
|
101.DEF
|
|
XBRL Taxonomy
Extension Definition Linkbase
|
101.LAB
|
|
XBRL Taxonomy
Extension Label Linkbase
|
101.PRE
|
|
XBRL Taxonomy
Extension Presentation Linkbase
|
SIGNATURES
Pursuant to
the requirements of Section 13 or 15(d) of the Securities Exchange
Act of 1934 the registrant has duly caused this report to be signed
on its behalf by the undersigned, thereunto duly
authorized.
Registrant
Date: May
14, 2021
|
FitLife Brands, Inc.
By: /s/ Dayton
Judd
|
|
|
Dayton
Judd
|
|
|
Chief
Executive Officer and Chair
(Principal
Executive Officer)
|
Registrant
Date: May
14, 2021
|
FitLife Brands, Inc.
By: /s/ Susan
Kinnaman
|
|
|
Susan
Kinnaman
|
|
|
Chief
Financial Officer
(Principal
Financial Officer)
|
- 23 -